- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03285204
Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia
February 25, 2019 updated by: Jose Luis Urcelay Segura
The aim of this study is to obtain an early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia which allows to diagnose the disease in an initial stage and to follow up the patient with optic coherence tomography, a fast, non-invasive and comfortable method
Study Overview
Status
Unknown
Conditions
Detailed Description
All patients will be asked about their data and their general medical history, and will be underwent on one hand, a complete neurological examination including the degree of neurological impairment quantified according to the functional rating scale of ALS (ALSFRS-r) or Scale for the assessment and rating of ataxia (SARA); On the other hand, they will have a complete ophthalmological examination too, including the patient's graduation, pupillary and ocular motility examination, biomicroscopy, Goldman tonometry and fundus exam.
Patients will be performed too a conventional automated Humprey perimetry, color test (Farnsworth-Munsell 28 Hue Color Vision Test) and finally an optical coherence tomography (OCT) in order to see possible anatomical alterations in both macula and optic nerve.
The follow-up of these explorations will be repeated in all cases at 6 months.
Study Type
Observational
Enrollment (Anticipated)
90
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pilar Rojas, MD
- Phone Number: +34616042758
- Email: pilar.rojas.lozano@gmail.com
Study Locations
-
-
-
Madrid, Spain, 28010
- Recruiting
- Pilar Rojas Lozano
-
Contact:
- Pilar Rojas Lozano
- Phone Number: +34616042758
- Email: pilar.rojas.lozano@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Amyotrophic lateral sclerosis patients Friedreich's ataxia patients Healthy volunteers
Description
Inclusion Criteria:
- Older than 18 years.
- Best corrected visual acuity more than 0.4 (20/50 Snellen = 0.4 logMAR = 65 ETDRS letters).
- Refractive defect less than 5 diopters of spherical equivalent and / or cylinder less than 2 diopters.
- Transparent optical media: Opacity of crystalline <1 according to Lens Opacities Classification System (LOCS) III.
- Open anterior chamber angle assessed by gonioscopy with Goldmann lens (grade> III).
- Availability and collaboration to carry out the tests of the exploratory protocol.
- Acceptance of informed consent.
Exclusion Criteria:
- Previous intraocular surgeries of less than 6 months of evolution. Patients with refractive surgery using the LASIK or LASEK technique will not be excluded.
- Physical or mental difficulties to perform reliable and reproducible perimeters.
- Pathology and / or ocular malformations, angular or optic nerve anomalies.
- Any retinopathy or maculopathy.
- Intraocular pressure (IOP)> 21 mmHg.
- Signal-to-noise ratio in OCT less than 5/10.
- Failure to meet any inclusion criteria.
- Mental retardation or any other limitation in obtaining informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
ALS patients
|
Friedreich Ataxia patients
|
Healthy control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia
Time Frame: change from baseline to 6 month
|
macular, ganglion cell layer and retinal nerve fiber layer thickness measure
|
change from baseline to 6 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jose L Urcelay, PhD, Hgu Gregorio Maranon
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2015
Primary Completion (Anticipated)
January 1, 2020
Study Completion (Anticipated)
February 1, 2020
Study Registration Dates
First Submitted
March 8, 2017
First Submitted That Met QC Criteria
September 12, 2017
First Posted (Actual)
September 15, 2017
Study Record Updates
Last Update Posted (Actual)
February 26, 2019
Last Update Submitted That Met QC Criteria
February 25, 2019
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Heredodegenerative Disorders, Nervous System
- Sensation Disorders
- Mitochondrial Diseases
- Cerebellar Diseases
- Spinocerebellar Degenerations
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Friedreich Ataxia
- Vision, Low
- Vision Disorders
Other Study ID Numbers
- ELA-AF-OCT-2014-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted